1. Daiichi Sankyo Inc. Enhertu (fam-trastuzumab deruxtecan-nxki): US prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf. Accessed 2020.
2. Daiichi Sankyo Company Ltd, AstraZeneca. Daiichi Sankyo and AstraZeneca announce global development and commercialization collaboration for Daiichi Sankyo’s HER2 targeting antibody drug conjugate [fam-] trastuzumab deruxtecan (DS-8201) [media release]. 29 Mar 2019. http://www.daiichisankyo.com.
3. AstraZeneca. AstraZeneca and Daiichi Sankyo enter collaboration for novel HER2-targeting antibody-drug conjugate [media release]. 28 Mar 2019. https://www.astrazeneca.com/.
4. Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173–85.
5. Daiichi Sankyo Company Ltd. Daiichi Sankyo advances [fam-] trastuzumab deruxtecan (DS-8201) in Japan with regulatory submission in HER2 positive metastatic breast cancer [media release]. 9 Sep 2019. http://www.daiichisankyo.com.